Form 4: Graf Acquisition Partners IV LLC Reports Share and Warrant Distribution in NKGen Biotech

Graf Acquisition Partners IV LLC distributed shares and warrants of NKGen Biotech to its members following the one-year anniversary of the business combination.

Summary

• Graf Acquisition Partners IV LLC, a significant shareholder in NKGen Biotech, has reported the distribution of 63,634 common shares to its members.
• This distribution occurred on December 20, 2024, following the one-year anniversary of the business combination between Graf Acquisition Corp. IV and NKGen Biotech.
• The distribution also included 757,942 private placement warrants and 93,334 working capital warrants to members of Graf Acquisition Partners IV LLC.
• These warrants are exercisable at $11.50 per share and expire on September 29, 2028.
• The private placement warrants were initially purchased at $1.50 each, and the working capital warrants were issued in connection with the conversion of working capital loans at $1.50 each.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of share and warrant distribution, which is neither particularly positive nor negative. It is a standard procedure following a business combination.

Positives

• The distribution of shares and warrants to members of Graf Acquisition Partners IV LLC is a standard procedure following the lock-up period of the business combination.
• The warrants provide potential future upside for the recipients if NKGen Biotech's share price increases above the exercise price of $11.50.

Negatives

• The distribution of shares could potentially increase the supply of shares in the market, which could exert downward pressure on the stock price.

Risks

• The exercise of the warrants could lead to dilution of existing shareholders' equity.
• The market price of NKGen Biotech's stock may not reach the $11.50 exercise price of the warrants before their expiration on September 29, 2028.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance, but the warrants represent a potential future source of capital if exercised.

Management Comments

• James A. Graf, managing member of Graf Acquisition Partners IV LLC, has voting and investment discretion with respect to the securities held of record by the Sponsor.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership following a business combination and is common in the SPAC (Special Purpose Acquisition Company) lifecycle.

Comparison to Industry Standards

• The distribution of shares and warrants to members of a SPAC sponsor is a standard practice after the lock-up period following a business combination.
• The warrant terms, including the $11.50 exercise price and the September 29, 2028 expiration date, are typical for warrants issued in SPAC transactions.
• Similar distributions can be seen in other SPAC transactions such as the distribution of shares and warrants by the sponsors of companies like Lucid Motors and DraftKings after their respective mergers.

Stakeholder Impact

• The distribution of shares could potentially impact the share price of NKGen Biotech.
• The warrant distribution provides potential future upside for the recipients.

Key Dates

Keywords

NKGen Biotech, Graf Acquisition Partners IV LLC, share distribution, warrants, private placement warrants, working capital warrants, beneficial ownership, SEC Form 4